Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors

202036 citationsJournal Articlegold Open Access

Authors

PsP occurred in 3.7% of NSCLC patients under ICI treatment. Based on iRECIST scheme, PsP and TBP may be associated with survival benefit.

Good health and well-being

Published in: OncoImmunology

Volume 9, Issue 1, pp. 1776058-1776058

Field-Weighted Citation Impact: 1.67